Rubius Therapeutics Stock (NASDAQ:RUBY)
Previous Close
$0.06
52W Range
- - $0.38
50D Avg
$0.02
200D Avg
$0.02
Market Cap
-
Avg Vol (3M)
$99.53K
Beta
2.21
Div Yield
-
RUBY Company Profile
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.